Biotech Values

[Mufaso]

VKTX may indeed have the first quad agonist in the clinic. Per the CC last night, it likely will happen and be available in both subq and oral forms.

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Next year, Viking expects to file a request with the Food and Drug Administration to begin testing in people a drug that mimics the activity of hormones called amylin and calcitonin. Amylin helps control blood sugar while calcitonin regulates calcium levels in the blood.

William Blair analyst Andy Hsieh noted Viking is also testing a combination of the amylin/calcitonin drug with its experimental injection, VK2735. The latter mimics the GLP-1 and GIP hormones to improve feelings of satiety and slow how fast the stomach empties.

Lilly, on the other hand, already has an approved obesity drug that targets GLP-1 and GIP called Zepbound. It's also working on a triple regimen that loops in a third hormone, called glucagon. That drug is called retatrutide or, sometimes, GGG.

"Step aside, Triple G!" Hsieh said in a note. The "potential quad combo could generate considerable interest."

https://www.investors.com/news/technology/viking-therapeutics-stock-quad-eli-lilly-triple/